

AMENDMENTS

In the Claims:

D1  
Sub E2  
38. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered subcutaneously.

D2  
Sub E6  
41. (Amended) A method according to any of claims 38-40 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].

D3  
Sub E7  
43. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist delays gastric emptying and wherein said glucagon-like peptide 1 (7-36) amide agonist is administered subcutaneously.

D4  
Sub E8  
46. (Amended) A method according to any of claims 43-45 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-37) [(7-36)].